Comparison of proportional and differential odds models for mixed-effects analysis of categorical data
暂无分享,去创建一个
Mats O. Karlsson | Maria C. Kjellsson | E. Niclas Jonsson | M. Karlsson | M. Kjellsson | E. Jonsson | Per-Henrik Zingmark | P. Zingmark | E. Niclas Jonsson | Mats O. Karlsson
[1] N. Mayo,et al. Statistical assessment of ordinal outcomes in comparative studies. , 1997, Journal of clinical epidemiology.
[2] M. Dowsett,et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] David Hinkley,et al. Bootstrap Methods: Another Look at the Jackknife , 2008 .
[4] D. Stram,et al. Variance components testing in the longitudinal mixed effects model. , 1994, Biometrics.
[5] Mats O Karlsson,et al. Pharmacokinetics of Ximelagatran and Relationship to Clinical Response in Acute Deep Vein Thrombosis , 2005, Clinical pharmacology and therapeutics.
[6] B. Efron. Bootstrap Methods: Another Look at the Jackknife , 1979 .
[7] J. Verweij,et al. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea , 2002, Clinical pharmacology and therapeutics.
[8] Mats O. Karlsson,et al. Use of Prior Information to Stabilize a Population Data Analysis , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[9] A. Agresti. Categorical data analysis , 1993 .
[10] L B Sheiner,et al. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data , 1994, Clinical pharmacology and therapeutics.
[11] D. Mould,et al. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors , 2002, Clinical pharmacology and therapeutics.
[12] Laura Iavarone,et al. Population Pharmacokinetic-Pharmacodynamic Model of Craving in an Enforced Smoking Cessation Population: Indirect Response and Probabilistic Modeling , 2001, Pharmaceutical Research.
[13] Lynn McFadyen,et al. A Two-Part Mixture Model for Longitudinal Adverse Event Severity Data , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[14] D R Stanski,et al. Population pharmacodynamic model for ketorolac analgesia , 1996, Clinical pharmacology and therapeutics.
[15] Mats O. Karlsson,et al. Assessment of Type I Error Rates for the Statistical Sub-model in NONMEM , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[16] L B Sheiner,et al. Quantitative characterization of therapeutic index: Application of mixed‐effects modeling to evaluate oxybutynin dose–efficacy and dose–side effect relationships , 1999, Clinical pharmacology and therapeutics.
[17] Erik Olofsen,et al. Alfentanil and Placebo Analgesia: No Sex Differences Detected in Models of Experimental Pain , 2005, Anesthesiology.
[18] J. DeJongh,et al. Population pharmacokinetic and pharmacodynamic modeling of propofol for long‐term sedation in critically ill patients: A comparison between propofol 6% and propofol 1% , 2002, Clinical pharmacology and therapeutics.
[19] Mats O Karlsson,et al. Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. , 2003, British journal of clinical pharmacology.
[20] Mats O Karlsson,et al. Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. , 2004, British journal of clinical pharmacology.
[21] B. Armstrong,et al. Ordinal regression models for epidemiologic data. , 1989, American journal of epidemiology.
[22] J Wakefield,et al. Cumulative logit models for ordinal data: a case study involving allergic rhinitis severity scores , 2001, Statistics in medicine.
[23] D. Bates,et al. Mixed-Effects Models in S and S-PLUS , 2001 .
[24] D. Mould,et al. A population pharmacokinetic‐pharmacodynamic and logistic regression analysis of lotrafiban in patients , 2001, Clinical pharmacology and therapeutics.